Regadenoson Hydrate

瑞加诺生

Report date: 2025/03/19 09:54:47
NMEFirst In Class

Base Information

Drug NameRegadenoson Hydrate
Drug Alias Nameregadenosonum瑞加迪松瑞加德松瑞加诺生类伽腺苷 +[9] 
ClassificationSmall moleculesDiagnostic agent (In vivo) > Contrast agent
Mechanisms of ActionAdenosine A2a receptor agonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Contrast agents +[16] 
Global Approved IndicationsContrast agentsDiagnostic agentsCardiovascular contrast agents
Approved Indications in ChinaDiagnostic agentsCardiovascular contrast agents
Original Approved Country/TerritoryUnited States
Original Approved Date2008/04/10
Country/TerritoryUnited StatesPuerto RicoItaly +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesGe HealthcareGe Healthcare AsAstellas Pharma Inc +[5] 
Inactive CompaniesDana-Farber Cancer InstituteAstellas Pharma Us IncWashington University School Of Medicine +[13] 
Active IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Contrast agents +[8] 
Inactive IndicationsAnemia, Sickle CellHeart DiseasesCardiovascular Diseases +[8] 

Other Information

ATC CodeC01EB21
Related LinksWikipediaDrugBankKEGG